Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07109817 · ClinicalTrials.gov registry record · Phase 2
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer
A Phase 2 study, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT07109817 is a Phase 2 study that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 116 participants.
The verdict
NCT07109817, a Phase 2 study, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.
Interventions
- DRUG Placebo
- DRUG Desloratodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07109817
The ClinicalTrials.gov registry entry for NCT07109817 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07109817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07109817 about?
NCT07109817 is a clinical study titled "Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer". This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug...
What is the current status of trial NCT07109817?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2026-06. Estimated completion is 2030-09.
What interventions are being tested in trial NCT07109817?
The interventions under investigation include: Placebo (DRUG), Desloratodine (DRUG).
Who is sponsoring clinical trial NCT07109817?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.